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Haemophilus influenzae type b used to be the cause of most
bacterial meningitis in children from North America and
Europe, a fact that changed with systematic vaccination with
anti-H. influenzae type b vaccine [1]. Pre-vaccination incidence
was much lower in Catalonia, an autonomous Spanish com-
munity, where only 7.4% of reported cases of men-
ingoencephalitis were due to H. influenzae (data from the
Microbiological Notification System) and the reported inci-
dence rates of invasive disease in children under 5 years old
during 1993, 1994 and 1995 were, respectively, 7.1, 9.6 and
11.8 per 100 000, values clearly lower than those from other
zones [2].
H. influenzae was, until some years ago, uniformly susceptible
to ampicillin and chloramphenicol. However, there are increas-
ing rates of resistance to these antibiotics, and the use of cephalo-
sporins for the treatment of infections produced by this
microorganism is accepted worldwide [3,4].
This paper presents a prospective study on the incidence of
H. influenzae meningitis in pediatric and adult patients. It was
developed in Catalonia during 1996 and 1997, when some
pediatricians used to vaccinate their patients but this was not a
systematic practice. Patients attending all 68 centers belonging
to the Catalan Hospital Network were included in the study.
The population of Catalonia is 6 096 621, 268 424 of them
under 5 years old (1996 census).
The objectives were to determine the incidence of H.
influenzae meningitis as well as the bacteriologic characteristics
of the microorganism and its patterns of resistance to different
antibiotics.
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All cases with a microbiological diagnosis of H. influenzae
meningitis detected during the above-mentioned 2-year period
were collected using an active surveillance method. The estab-
lished criteria for microbiological positivity was isolation of the
microorganism from cerebrospinal fluid (CSF) and/or blood
(detection of antigens or genomic sequences did not add any
new positive result).
One hundred and ninety-four cases of invasive disease caused
by H. influenzae were detected during the 2 years of the study,
51 of them (26.2%) in children less than 5 years old. Encap-
sulated strains belonging to serotype b were responsible for
36.6% of infections, but this percentage was higher (76.5%) in
patients under 5 years. Systematic vaccination of the pediatric
Catalan population had not yet been introduced in the vac-
cination calendar during the period of the study, but the vaccine
was available in pharmacies. The estimated coverage (based on
the examination of 557 individual vaccination cards randomly
selected from all the private and public day-care and preschool
centers of Catalonia) was about 32% in children under 5 years
old.
Strain identification was according to their requirement for X
(hemin) and V (b-nicotinamide adenine dinucleotide) growth
factors.
Biotype was determined on the basis of urease, indole and
ornithine decarboxylase production.
Serotype was determined by means of a coagglutination tech-
nique with antiserum against serotype b capsular polysaccharide
(Phadebact Hi type b, Boule Diagnostics, Huddinge, Sweden)
and polyvalent antiserum for serotypes a, c, d, e and f (Phadebact
Hi types a, c–f, Boule Diagnostics); in the case of positivity of
the pool a, c–f, serotype level was reached with specific antisera
(H. influenzae Agglutinating Sera, Murex Diagnostics, Dartford,
England).
The presence of b-lactamase was detected with nitrocefin
disks (BBL Cefinase, Becton Dickinson, Cockeysville, MD,
USA).
The antibiotic susceptibility study was performed with E
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Table 1 Strain distribution by biotype and serotype among children and adults
No. of strains belonging to each biotype
Age (years) I II III IV VII
 5 years 16/0a 2/0 1/0 0/1 1/0
5–18 years 0 0/1 0 0 0
 18 years 0/1 1/6 0/1 0 0
aSerotype.
test strips (AB Biodisk, Solna, Sweden) on HTM medium
(Haemophilus Test Medium, Becton Dickinson). Minimal
inhibitory concentrations (MICs) for ampicillin, amoxy-
cillin/clavulanic acid, cefotaxime, cefuroxime and chlo-
ramphenicol were determined with this methodology.
Susceptibility breakpoints were established according to the
National Committee for Clinical Laboratory Standards
(NCCLS) recommendations for H. influenzae [5].
Statistical study of all data was based on the chi-square test. A
difference between groups was considered to have significance
when P  0.05, with one degree of freedom and a risk a = 0.05.
Thirty-six strains of H. influenzae were isolated from patients
affected by meningitis, aged 2 months to 83 years. Children
under 5 years of age predominated (63.9%) over older patients;
there was an age peak at  1 year old (41.7%). These data
indicate an annual incidence of H. influenzae meningitis of 0.3
per 100 000 inhabitants, and of 4.3 per 100 000 children under
the age of 5. Meningitis represented 18.6% of all invasive dis-
eases in the total population and 45.1% in children under 5.
Distribution according to gender was 50 : 50. Although males
were more prevalent (73.7%) under the age of 2, there were
more females (76.5%) over that age (P  0.001).
Thirty-four out of 36 strains were serotyped; the remaining
two strains could not be subcultured and died. Of 34 strains,
23 (67.7%) belonged to serotype b, 21 of them isolated from
children and two from women aged 49 and 83 (the first one
suffered from chronic otitis media and the second one had no
related previous pathology), and 11 strains (32.4%) were non-
typable, two of them isolated from children (one boy aged 5
months without any other pathology, and another 9-year-old
boy suffering from lymphoma) and nine isolated from adults.
No other serotype was detected. Pediatric serotype b strains
were isolated from 14 patients under 1 year old, two patients
aged between 1 and 2 years, and five patients aged 2–5 years.
Biotype distribution was: 17 strains (54.8%) biotype I, 10
strains (32.3%) biotype II, two strains (6.5%) biotype III and
one strain (3.23%) belonging to each one of biotypes IV and
VII. There were five strains whose biotype could not be deter-
mined.
Table 1 correlates patients’ ages with biotypes and serotypes
of the strains that infected them. There is a different distribution
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between type b strains belonging to biotype I, which infected
mostly pediatric patients, and non-typable strains belonging to
biotype II, which infected mostly adults (P  0.005).
b-Lactamase was produced by 42.4% of strains, and it was
the only mechanism for ampicillin resistance detected among
our isolates. The MIC of this antibiotic was always  256 mg/L
in resistant strains, and the MIC50 was 0.5 mg/L. All tested
strains were susceptible to cefotaxime and cefuroxime. The
four strains that showed the highest cefuroxime MIC (3 mg/L)
were not b-lactamase producers. The resistance rate to chlo-
ramphenicol was 26.7%, and all strains resistant to this antibiotic
were b-lactamase producers.
The 14 ampicillin-resistant strains were isolated from patients
under 5 years old. Six serotype b strains isolated from patients
3 years old or younger were simultaneously resistant to ampi-
cillin and chloramphenicol; five of them belonged to biotype
I and one to biotype II.
Most ampicillin-resistant strains belonged to serotype b
(92.9%), and 59.1% of serotype b strains were ampicillin resist-
ant, while only 9.1% of non-typable ones were resistant to this
antibiotic (P  0.01).
The results of our series, obtained by means of an active
surveillance program, show an annual incidence of H. influenzae
meningitis of 0.3 per 100 000 inhabitants per year (4.3 in pat-
ients under 5 years old). They are similar to results obtained in
the same geographic area based on obligatory reporting of
the illness or on microbiological notification [6], which reveal
annual incidences of H. influenzae meningitis of 0.4 per 100 000
(3.1–7.1 per 100 000 in children under 5 years old) [7]. Our
data are lower than those obtained in other areas of Spain,
which report values between 4.7 and 14 per 100 000 children
under 5 years of age [8], and much lower than data from other
countries in Europe (25.1 per 100 000 children under 5), North
America (1.9–4.0 per 100 000) and even from Mediterranean
countries (8.3 per 100 000 children under 5 in the Athens
area) before the establishment of systematic vaccination of the
pediatric population [9–11]. The role of meningitis in the con-
text of all invasive diseases produced by this microorganism
presents great variability, which may be due in part to noti-
fication problems: invasive disease caused by H. influenzae does
not have very specific symptomatology, and this could explain,
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in the absence of an active surveillance program, the higher
proportion of reported meningitis than that of other clinical
forms of invasive disease which are not so relevant. Data from
Catalonia during the years 1992–94 [12] showed that meningitis
represented 63.7% of all invasive diseases caused by this micro-
organism in children under 5 years old, while the corresponding
figure in our series was 45.1%. Data on meningitis incidence
are also higher than ours in many other publications, such as
those from other regions of Spain, where it was about 63%
from 1981 to 1990 [13]. They have even higher relative import-
ance in other countries such as Great Britain, where they rep-
resented 70% of all invasive diseases from 1985 to 1991 [9].
The preference for early ages of life, before the age of 5, is well
documented, as is the predominance of males over females
among children with meningeal infections [9–14]. This is also
demonstrated by our data, with a male/female ratio of 1.9.
It is interesting to note that all encapsulated strains belonged
to serotype b. On the other hand, the prevalence of encap-
sulated strains (and specifically of serotype b) or non-encap-
sulated strains among those producing meningitis is related to
the age of the affected patients: in a national study performed
in The Netherlands between 1976 and 1990, serotype b was
100 times more frequent among strains producing meningitis
in children less than 10 years old than among those infecting
adults, while non-typable strains were twice as frequent among
adults as among children [15]. There is also an age-related
tropism in our series, since 91% of type b strains affected chil-
dren under 5 years old, while non-typable strains produced
meningitis in patients older than 10 years in 82% of cases.
Data similar to ours on the frequency of biotypes I and II in
cases of meningitis have been reported by different authors in
Brazil, Finland and South Africa [16,17], who have mentioned
the association of infection by biotype I strains with patients 10
years old or younger and of biotype II with adult patients, as
occurs in our series.
The existence of H. influenzae strains with ampicillin resist-
ance mechanisms different from b-lactamase production has
been described during the last few years [18]. In fact, PBP
alteration has been proposed as a possible origin of these
BLNAR (b-lactamase-negative ampicillin-resistant) strains.
However, this alternative mechanism was not detected in our
series, which has 42.4% ampicillin-resistant strains, all of them
susceptible to the combination of amoxycillin and clavulanic
acid. This percentage is similar to the average for the rest of
Spain, according to a multicenter study carried out in 1990
[19]. This established differences in b-lactamase production
of invasive strains (from 14.3% to 68.8%) according to their
geographic origin and to the age of infected patients. The
high resistance rate in pediatric isolates is related to the high
proportion of resistant strains belonging to serotype b, since this
capsular type is prevalent among children. In spite of the high
rate of b-lactamase production of our strains, the good activity
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of all tested cephalosporins is outstanding: all strains were sus-
ceptible to cefotaxime (with the lowest MIC range of all tested
antibiotics) and cefuroxime.
The chloramphenicol resistance level in our series (26.7%)
and in the rest of Spain is much higher than in Anglo-Saxon
countries [9–19]; the association of chloramphenicol and
ampicillin resistance rules out this antibiotic as an alternative to
empirical therapy.
The low incidence rate of H. influenzae meningitis in Cat-
alonia during 1996 and 1997 is noteworthy; this was a period
with a low level of child vaccination coverage. It was mostly
due to type b biotype I encapsulated strains in children and to
non-typable biotype II strains in adults. It is also remarkable
that the ampicillin resistance found in 42.4% of isolates, mostly
type b strains, was due to b-lactamase production.
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